Filter News

Rigel Pharmaceuticals, Inc. to Host Conference Call Today to Discuss Its Partnership With AstraZeneca PLC on Fostamatinib Disodium (R788)

Published: Feb 16, 2010

SOUTH SAN FRANCISCO, Calif., Feb. 16 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. announced that its senior management team will host a conference call, and simultaneous audio webcast, today at 8:30 a.m. EST (5:30 a.m. PST) to discuss its partnership with AstraZeneca for Rigel's late-stage investigational product, fostamatinib disodium (R788), for the treatment of rheumatoid arthritis and additional indications.

About Rigel (www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

Photo: http://www.newscom.com/cgi-bin/prnh/20030226/RIGLLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk photodesk@prnewswire.comRigel Pharmaceuticals, Inc.




Back to news